Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
1.18 M
Value Traded
5.58 M
Short % Float
3.15%
+0.19%Week
-8.18%1 Month
+18.03%3 Month
-7.22%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.05 B
EPS (TTM)
-2.47
P/E Ratio
-
Ent. Value
1.93 B
Total Shares
192.57 M
Float Shares
162.61 M
Insiders
15.55%
Institutions
17.76%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TRLV Catalyst Timeline
Dated clinical, regulatory and corporate events for Trulieve Cannabis Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Trulieve Cannabis Corp.
85Total events
2Upcoming
7Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Other Regulator MilestoneEx-US Regulatory
DEA inspections completed in Florida, Pennsylvania, and West Virginia
▲Product LaunchPost-Market
Launch of Modern Flower and Roll One branded vape and inhalable flower products in Georgia
●Other Regulator MilestoneEx-US Regulatory
Trulieve completes redomicile from British Columbia to Delaware
▲Product LaunchPost-Market
First sale commemorating Georgia medical cannabis program expansion
medical cannabissource ↗
◆Other Regulator MilestoneEx-US Regulatory
Hearing to review classification of marijuana begins
marijuanasource ↗
▲Other Regulator MilestoneEx-US Regulatory
Georgia SB 220 signed into law expanding medical cannabis program
medical cannabissource ↗
▲Other Regulator MilestoneEx-US Regulatory
Filed applications for DEA registration for 206 retail locations following Schedule III rescheduling
medical marijuanasource ↗
▼Equity OfferingCorporate
Closed $60 million private placement of senior secured notes due 2030
▲Quarterly UpdateCorporate
Generated $109 million cash flow from operations in first half of 2026
▲Product LaunchPost-Market
Launch of Modern Flower and Roll One branded vape and inhalable flower products in Georgia
▲Debt Royalty FinancingCorporate
Closed US$140 million private placement of 10.5% Senior Secured Notes due 2030
▼Debt Royalty FinancingCorporate
US$100 million private placement of 10.5% Senior Secured Notes due 2030
▲Product LaunchOnwardPost-Market
Expanded distribution of Onward premium THC beverages in Florida and Illinois
▲Debt Royalty FinancingCorporate
Announced planned redemption of $368M senior secured notes due 2026
▲Debt Royalty FinancingCorporate
Notice of redemption for all US$368M 8.0% senior secured notes due 2026
●Partnership / LicenseCorporate
Entered partnership with Professional Pickleball Association and Major League Pickleball
▲Quarterly UpdateCorporate
Trulieve reports Q2 2024 revenue of $303M, up 2% sequentially and 8% YoY
▲Product LaunchPost-Market
Launched adult use sales in Ohio at three locations (Beavercreek, Columbus, Westerville)
◆Other Regulator MilestoneEx-US Regulatory
Florida Supreme Court ruling deadline for adult-use initiative
adult-use cannabissource ↗
▲Debt Royalty FinancingCorporate
Notice of redemption for all US$130M 9.75% senior secured notes due 2024
●Other Regulator MilestoneEx-US Regulatory
Smart and Safe Florida campaign presented oral arguments to Florida Supreme Court
adult-use cannabissource ↗
▲Debt Royalty FinancingCorporate
Purchased $57M face value senior secured 2026 notes at 16.5% discount
Past FDA Catalysts and PDUFA Decisions
How TRLV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every TRLV program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rivers Kim A.Director, Officer (Chairman and CEO), 10% Owner | Sell | -136,811 1,476,913 held | $8.76 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TRLV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TRLV for Q2 2026. | ||||
TRLV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TRLV ranks across every disease it competes in
Competitive Position is a premium feature
See how TRLV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTRLV News
-TRLV
Oct 6, 2026Trulieve Cannabis Corp. to Hold Third Quarter 2026 Results Conference Call on November 5, 2026
Trulieve Cannabis Corp. will conduct a conference call on November 5, 2026, at 8:30 AM ET to discuss its third quarter 2026 financial results. CEO Kim Rivers and CFO Jan Reese will lead the call, which can be accessed via phone or a live audio webcast. The company is recognized as a top performer in the medical cannabis sector.
Read more →-TRLV
Sep 22, 2026▲ +8.4%on this news
Trulieve Cannabis Corp. Added to S&P Total Market and S&P Completion Indices
Trulieve Cannabis Corp. has been added to the S&P Total Market Index and S&P Completion Index, marking a significant milestone for the company. This inclusion is anticipated to improve liquidity and attract institutional investors, further enhancing Trulieve's presence in the U.S. capital markets. The company continues to focus on expanding access to cannabis through its operations across several states.
Read more →-TRLV
Sep 4, 2026Trulieve to Open Medical Cannabis Dispensary in Dunwoody, Georgia
Trulieve Cannabis Corp. is set to open a new medical cannabis dispensary in Dunwoody, Georgia, on September 10, 2026. This location aims to enhance access to medical cannabis for patients in the Metro Atlanta area. The grand opening will feature a ribbon cutting, food trucks, discounts, and merchandise giveaways, showcasing Trulieve's commitment to community engagement.
Read more →-TRLV
Sep 2, 2026Trulieve Announces September 2026 Event Participation
Trulieve Cannabis Corp. has announced its participation in two key investor conferences in September 2026. Christine Hersey, the Chief Corporate Affairs and Strategy Officer, will attend the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference on September 9. Additionally, CEO Kim Rivers will participate in the 5th Annual Roth Healthcare Opportunities Conference on September 29.
Read more →-TRLV
Aug 18, 2026Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE
Trulieve Cannabis Corp. celebrated its historic listing on the NYSE by ringing The Closing Bell. This event marks Trulieve as the first U.S. cannabis company to achieve this milestone, reflecting its leadership in the industry. CEO Kim Rivers emphasized the company's commitment to operational excellence and long-term shareholder value.
Read more →-TRLV
Aug 11, 2026Trulieve Completes Redomicile from British Columbia to Delaware
Trulieve Cannabis Corp. has successfully completed its redomicile from British Columbia to Delaware. This strategic move aims to enhance access to U.S. investors and improve eligibility for broader index inclusion. The redomicile was approved by shareholders and finalized on August 11, 2026, with shares continuing to trade under the ticker TRLV.
Read more →-TRLV
Aug 5, 2026▼ -5.1%on this news
Trulieve Announces August 2026 Event Participation
Trulieve Cannabis Corp. has announced its participation in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. Founder and CEO Kim Rivers will engage in a fireside chat and investor meetings during the event. The company continues to expand its operations across several states, emphasizing its commitment to providing high-quality cannabis products.
Read more →-TRLV
Jul 16, 2026Trulieve to Open Medical Cannabis Dispensary in Marco Island, Florida
Trulieve Cannabis Corp. announced the opening of a new medical cannabis dispensary in Marco Island, Florida, set to celebrate its grand opening on July 24. The dispensary will offer a variety of products, including in-house brands and partner brands. Trulieve aims to provide high-quality care and products to patients in the area.
Read more →-TRLV
Jul 10, 2026Trulieve Cannabis Corp. to Hold Second Quarter 2026 Results Conference Call on August 7, 2026
Trulieve Cannabis Corp. will hold a conference call on August 7, 2026, to discuss its second quarter financial results. The call will feature CEO Kim Rivers and CFO Jan Reese, who will review the company's performance. Interested parties can join the call via phone or listen to a live webcast.
Read more →-TRLV
Jul 10, 2026Trulieve Named to TIME's America's Best Companies 2026 List
Trulieve Cannabis Corp. has been named to TIME's America's Best Companies 2026 list, recognizing its strong employee satisfaction, financial performance, and sustainability practices. The company is one of only two cannabis firms to receive this honor, reflecting its commitment to expanding access to cannabis. CEO Kim Rivers emphasized the dedication of their team in achieving this recognition.
Read more →-TRLV
Jul 1, 2026Trulieve Commemorates Georgia Medical Cannabis Launch with First Sale
Trulieve Cannabis Corp. celebrated the launch of Georgia's expanded medical cannabis program with a ceremonial first sale in Marietta. The program now allows for a broader range of products, including flower and vaporization options, and expands qualifying conditions for patients. This initiative is seen as a significant advancement for patient access, especially for veterans. Trulieve plans to distribute products through pharmacies across Georgia.
Read more →-TRLV
Jun 26, 2026Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan
Trulieve Cannabis Corp. announced that CEO Kim Rivers plans to terminate her automatic securities disposition plan (ASDP) on August 11, 2026. The ASDP was initiated in March 2026 for the orderly sale of 2.5 million shares. The first tranche of share sales has been completed, and the second tranche was set to begin in September 2026. This decision may indicate confidence in the company's future performance.
Read more →-TRLV
May 7, 2026Trulieve Reports Profitable First Quarter 2026 Results Bolstered by Margins and Cash Flow Generation
Trulieve Cannabis Corp. reported a profitable first quarter of 2026 with revenue of $287 million, achieving a gross margin of 59%. The company also generated positive net income of $2 million and adjusted EBITDA of $100 million. Cash flow from operations was notable at $56 million, with a strong cash position of $353 million at quarter's end. The rescheduling of medical marijuana to Schedule III is expected to open new business opportunities for Trulieve as they expand their retail and operational footprint in various states.
Read more →-TRLV
Feb 26, 2026Trulieve Reports Fourth Quarter and Full Year 2025 Results with 60% Gross Margin and Record Cash Flow Generation Full year revenue of $1.2 billion, with 60% gross margin Record 2025 cash flow from operations of $273 mill
Trulieve Cannabis Corp. has released its financial results for the fourth quarter and full year ended December 31, 2025, reporting full year revenues of $1.2 billion, with a gross margin of 60%. Despite these achievements, the company faced a net loss of $116 million for the year. Key operational highlights include generating record cash flow from operations of $273 million and successfully growing its rewards program to 915,000 members. Management expressed optimism about future growth opportunities as they navigate the market landscape.
Read more →-TRLV
Dec 17, 2025Trulieve Announces Closing of US$140 Million Private Placement
Trulieve Cannabis Corp. has announced the closing of a private placement of 10.5% Senior Secured Notes due 2030, raising US$140 million in gross proceeds. The company intends to use the net proceeds for capital expenditures and general corporate purposes. The interest on the notes is payable semi-annually, and they are expected to mature on December 17, 2030. This fundraising effort reflects market demand as the offering size was increased accordingly.
Read more →-TRLV
Dec 9, 2025Trulieve Announces US$100 Million Private Placement
Trulieve Cannabis Corp. has announced a private placement of 10.5% Senior Secured Notes, expected to raise US$100 million. The Notes are due in 2030 and will be issued at face value. Proceeds from the offering will be utilized for capital expenditures and corporate purposes. The offering is anticipated to close by December 17, 2025, pending regulatory approval. Notably, the Notes will not be registered under the Securities Act, targeting qualified institutional buyers and certain non-U.S. persons for the sale.
Read more →-TRLV
Nov 5, 2025Trulieve Reports Third Quarter 2025 Results Demonstrating Operational Discipline and Cash Flow Strength
Trulieve Cannabis Corp. reported its third quarter 2025 financial results, showcasing a revenue of $288 million with a gross margin of 59%. Despite these promising figures, the company incurred a net loss of $27 million, though an adjusted net loss of $12 million was reported after excluding non-recurring charges. The company emphasized its operational discipline and cash flow strength, generating $214 million in cash flow from operations year-to-date. Trulieve also unveiled various product launches and expansions, underlining its growth trajectory in the cannabis market.
Read more →-TRLV
Nov 4, 2025Trulieve Announces Notice of Redemption for All
Trulieve Cannabis Corp. has announced the redemption of its outstanding 8.0% senior secured notes due 2026, totaling US$368 million. The redemption will occur on December 5, 2025, at 100% of the principal amount plus accrued interest. This decision reflects the company's strategy to manage debt effectively, indicating a solid financial standing. The notes will be delisted from the Canadian Securities Exchange following the redemption.
Read more →-TRLV
Aug 6, 2025Trulieve Reports Second Quarter 2025 Results Highlighting Progress on 2025 Plan
Trulieve Cannabis Corp. has released its financial results for the second quarter of 2025, reporting revenues of $302 million and a gross margin of 61%. The company increased its cash flow from operations to $137 million and launched new product lines, contributing to a growth in branded product sales. Despite this progress, Trulieve experienced a net loss of $14 million, illustrating challenges in profitability relative to operational expansion. The firm continues to execute its 2025 plan with an enhanced focus on customer engagement and product distribution.
Read more →-TRLV
May 7, 2025Trulieve Reports First Quarter 2025 Results Demonstrating Core Business Strength
Trulieve Cannabis Corp. reported its financial results for Q1 2025, demonstrating robust core business performance with a revenue of $298 million and a gross margin of 62%. Despite achieving positive cash flows and EBITDA growth, the company incurred a net loss of $33 million. The operational highlights include a significant increase in traffic and revenue from loyalty program members, alongside the launch of a new THC beverage product. However, rising operating expenses raise concerns about ongoing profitability.
Read more →About Trulieve Cannabis Corp.
Headquarters3494 MARTIN HURST ROAD, TALLAHASSEE, FL, 32312
BIOPHARMAWATCH ELITE PLUS
Trade the next TRLV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime